Table 1.

Existing evidence highlighting racial disparities in treatment-related CVD among patients with cancer.

Study	Year	Therapeutic intervention	Type of study	Definition of cardiotoxicity	Outcomes	Reference
Litvak et al.	2019	Trastuzumab +/− pertuzumab	Retrospective	LVEF decline to <50% and absolute drop in LVEF of ≥10% from baseline	Black patients had a higher rate of cardiotoxicity, and resultant incomplete adjuvant HER2-targeted therapy than white patients.	Cancer. 2018;124(9):1904–1911.
Hassan et al.	2004	Doxorubicin	Retrospective	CHF or a measured LVEF <45%.	African Americans had a higher rate of cardiotoxicity.	J Natl Med Assoc. 2004;96(2):196–199.
Al-Sadawi et al.	2021	Trastuzumab	Retrospective	Clinical heart failure (New York Heart Association class III or IV) or asymptomatic LVEF decline (absolute decrease ≥ 10% to < 53%, or ≥ 16%)	Risk of cardiotoxicity was significantly higher in black compared with white women (adjusted OR, 1.88; 95% CI, 1.25–2.84).	Am J Cardiol. 2021;147:116–121.
Baron et al.	2014	Trastuzumab	Retrospective	≥16% absolute decrease in LVEF from baseline or a ≥ 10% absolute decrease in LVEF from baseline with LVEF below institutional limits of normal (50%)	African Americans had a higher risk of developing decreased LVEF.	J Card Fail. 2014;20(8):555–559.

LVEF: left ventricular ejection fraction, HER2: human epidermal growth factor receptor 2, CHF: congestive heart failure, OR: Odd's ratio.